Lorus Therapeutics Inc. (LOR.TO,LRUSF.PK) announced that the Canadian Intellectual Property Office has issued the company's patent for its cancer immunotherapy agent, IL-17E.
According to Lorus, the Canadian patent protects the use of IL-17E to treat cancer, including many different solid tumors such as colon, breast, ovarian, pancreatic, and lung cancers as well as melanoma until 2026. In addition, the patent covers treatment of these cancers with IL-17E in combination with several approved anticancer therapeutics, including Avastin (bevacizumab), Gemzar (gemcitabine), Tarceva (erlotinib), Taxotere (docetaxel), Taxol (paclitaxel) and cisplatin.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.